This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Vimta Labs Q2 and H1 FY2026-27 results show revenue and profit growth
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 5.2 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved Q2 and H1 FY2026-27 results; amounts are in Rs million. Q2 revenue was 1,119.83, up about 10% year on year, and net profit was 206.14 versus 199.20. H1 revenue was 2,210.57 versus 1,994.12; profit was 416.56 versus 388.13; operating cash flow was 459.37. The review found no material misstatement. A prior-year 16.16 labour code charge was exceptional in FY2025-26. Wholly owned US subsidiary Vimta Labs LLC was incorporated.
Positive: revenue and profit grew with strong cash flow, supporting earnings. Q2 profit was slightly below Q1, while the US expansion adds risk.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹112.0 Cr | ₹101.8 Cr | +10.0% |
| Operating profit | ₹24.62 Cr | ₹23.62 Cr | +4.3% |
| Profit after tax | ₹20.61 Cr | ₹19.92 Cr | +3.5% |
| EBITDA margin | 33.8% | 33.6% | +0.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.